Navigation Links
FDA Panel Says No to Avastin for Advanced Breast Cancer
Date:12/5/2007

Drug has significant risks, and its benefits are still debated, experts say

WEDNESDAY, Dec. 5 (HealthDay News) -- A U.S. Food and Drug Administration advisory panel recommended Wednesday that the cancer drug Avastin should not be used to treat women with advanced breast cancer.

In a close vote, 5-4, the advisers decided the drug's ability to slow down the growth of tumors did not outweigh the increased risk of blood clots and other cardiovascular troubles among users, the Associated Press reported. In rare cases, patients taking Avastin with standard chemotherapy have died.

Avastin was approved to treat colon cancer in 2004, and lung cancer in 2006. It works by cutting off the tumor's blood supply.

"Everybody wants to offer metastic breast cancer patients hope, but we shouldn't offer them false hope," panel member Natalie Compagni-Portis, a patient representative with Breast Cancer Action in San Francisco, said during the meeting, according to the AP. "We have to raise the bar in terms of safety."

"These patients are terminal, and it's our job to make their lives better, not to say that it's OK to have a stroke or that it's manageable," Maha Hussain, an oncologist at the University of Michigan and the advisory panel's chairwoman, said during the meeting. "You didn't show that patients are living better or that they're living longer."

In trial results submitted to the FDA by the drug's U.S. maker, Genentech Inc., use of Avastin (bevacizumab) did boost the progression-free survival of women with advanced breast cancer by an average of 5.5 months, when combined with the chemotherapy drug paclitaxel. Progression-free survival refers to survival without any advancement of the malignancy.

However, the same Genentech study of 722 patients showed that patients reaped no gain in terms of their overall survival after taking Avastin.

Another company-funded trial, this ti
'/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
2. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
3. Patient Safety Authority Board of Directors Names Infection Advisory Panel
4. Partners Rx Chief Pharmacy Officer, Richard Bullard on Panel Discussion at the Fall 2007 Managed Markets Summit (MMS) in Phoenix, AZ.
5. Billians HealthDATA GM Speaking on Dreamforce 07 Panel
6. FDA Panel Recommends Approval of SyntheMeds REPEL-CV(R) Adhesion Barrier for Pediatric Patients
7. Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers
8. Health Courts Critic to be Featured Speaker at Wyoming Patient Safety Panel
9. FDA Panel Mulls Ban on Kids Cold Medicines
10. FDA Panel Weighs Ban on Kids Cold Medicines
11. FDA Panel Recommends Ban on Cold Medicines for Kids
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Panel Says No to Avastin for Advanced Breast Cancer
(Date:7/27/2015)... ... July 27, 2015 , ... At Champagne Smiles, they know that tooth ... can incur a lot of stress, pain, discomfort and embarrassment, which is why they ... treatment reaps the benefits of implants with the cost savings of dentures for anyone ...
(Date:7/27/2015)... ... July 27, 2015 , ... Recently, 10 Best Water ... water brands also made the organization’s list. As its name clearly indicates, 10 Best ... Here is a description of the top three brands, along with a listing of ...
(Date:7/27/2015)... ... ... In a creative effort to provide clear information about the process of ... Dove Tree in Lubbock has shared a new infographic to illustrate the process. The ... the nationally recognized collegiate program and traditional adult program at The Ranch at Dove ...
(Date:7/27/2015)... ... July 27, 2015 , ... The new ... diagnostics applications is rapidly increasing and is driven by focused research of pharmaceutical ... increasingly being evaluated for use in bio implants. MWCNTs are used in the ...
(Date:7/27/2015)... ... July 27, 2015 , ... SupplyLogic, a marketing execution ... on its newly redesigned company Website. In the blog, Founder and CEO Kevin Sherlock ... popular comedian: "Comedian George Wallace always asks: ‘Why is it the closer you get ...
Breaking Medicine News(10 mins):Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 2Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 4Health News:Best Water Brand Awards Presented by 10 Best Water 2Health News:The Ranch At Dove Tree Infographic Enlightens Process Of Recovery 2Health News:The Ranch At Dove Tree Infographic Enlightens Process Of Recovery 3Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 3Health News:SupplyLogic Releases First Executive Blog on Supply Chain Management Issues 2
... and relationships have helped many children reduce their levels of ... in August 2005, according to a new study. A second ... in the aftermath of the storm. The studies appear ... July/August 2010 issue of the journal Child Development . ...
... who survived the 2004 tsunami and ongoing civil war there ... to the youths, psychological health, but also daily stressors like ... after the disasters. The studies appear in a special ... of the journal Child Development . The first ...
... University of Texas MD Anderson Cancer Center remains the leading hospital ... according to the annual "Best Hospitals" survey published by U.S. News ... last nine years that MD Anderson has ranked number one in ... has been ranked one of the top two cancer hospitals in ...
... milk be avoided in the early months of an infant,s ... until baby starts eating solid food. But new research from ... cow,s milk in the first 15 days of life may ... Prof. Yitzhak Katz of Tel Aviv University,s Department of Pediatrics, ...
... Steven Reinberg HealthDay Reporter , WEDNESDAY, July 14 ... helps people drop pounds but does so with few side ... fighting the obesity epidemic, lorcaserin is a new type of ... associated with feelings of well-being and feeling full, and does ...
... HealthDay Reporter , WEDNESDAY, July 14 (HealthDay News) ... for Alzheimer,s disease for the first time in 25 years ... key change would put more focus on the various stages ... convened by the U.S. National Institute on Aging and the ...
Cached Medicine News:Health News:Hurricane Katrina's effects on children: Resilience and gender 2Health News:Sri Lankan children affected by war, tsunami, daily stressors 2Health News:MD Anderson keeps No. 1 cancer ranking in US News & World Report annual survey 2Health News:MD Anderson keeps No. 1 cancer ranking in US News & World Report annual survey 3Health News:Cow's milk does a baby good 2Health News:New Pill Found to Cut Weight With Few Side Effects: Study 2Health News:New Pill Found to Cut Weight With Few Side Effects: Study 3Health News:New Criteria for Alzheimer's Diagnosis Proposed 2Health News:New Criteria for Alzheimer's Diagnosis Proposed 3
(Date:7/27/2015)... DUBLIN , July 27, 2015 /PRNewswire/ ... has announced the addition of the ... Competitors And Opportunities: 2015-2020 Analysis And Forecasts" ... Comprehensive information and evaluation of the ... analysis of manufacturers, segmentation, product offerings, competitive ...
(Date:7/27/2015)...   DocResponse was ranked the most ... peer-reviewed study , "Evaluation of symptom checkers ... in the July issue of The British Medical ... School researchers determined that performance of online symptom ... diagnosis first in standardized patient evaluations more often ...
(Date:7/27/2015)... 2015 Syneron Medical Ltd. ... market leader in the aesthetic medical device marketplace, announced ... and Drug Safety (MFDS) regulatory clearance for the PicoWay® ... fulfill PicoWay orders from its Korean distribution partner, with ... the third quarter 2015. Amit Meridor, Chief ...
Breaking Medicine Technology:Global Wound Care Markets 2015-2020 - Traditonal, Advanced And Regenerative: Competitors And Opportunities 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 2Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 4
... Ortho-McNeil to Continue Investigation of GDIR Agonists Under its ... ... 7 Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today ... discovered by Arena and being investigated,for the treatment of type ...
... Phase 2 Program to Provide Initial Proof-of-Concept Data ... ... 7 VIA Pharmaceuticals,(Nasdaq: VIAP ), a biotechnology company focused ... today that,it has enrolled the first patient in its Phase 2 ...
Cached Medicine Technology:Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 2Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 3Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 4VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 2VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 3VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 4VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation 5
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: